Tg Immunopharma Has Announced That The Fda Has Approved The Clinical Investigation Of Tgi-6, For The Development Of Breakthrough Bispecific Antibody.Tgi-6 Is A Novel Antibody Developed To Target Both Tumour-Associated Antigens (Taa) And Cd3 Molecules. This Dual Targeting Mechanism Is Designed To Enhance Anti-Tumour Responses. By Binding To Taas, Which Are Specific To Cancer Cells, Tgi-6 Can Directly Recognise And Attack Tumour Cells.Tgi-6, A Novel Therapeutic Agent, Has Been Specifically Engineered To Uphold Potent Cytotoxic Effects While Mitigating The Potential For Cytokine Release Syndrome (Crs). Tgi-6 Has Demonstrated Superior Antitumor Activity And Safety In Preclinical Studies.Tgi-6 Taa Is Highly Expressed In Several Solid Tumours, Including Colon Cancer, Breast Cancer, Hepatocellular Carcinoma, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer And Many Others. This Makes Tgi-6 A Promising Candidate For The Treatment Of Many Solid Tumours.Preclinical Investigations Have Showcased The Remarkable Potential Of Tgi-6, As It Achieved Complete Regression Of Tumours In Animal Models Of Colourectal Cancer Following A Single Administration. Tgi-6 Is Specifically Designed To Uphold Potent Cytotoxic Activity While Mitigating The Potential For Cytokine Release Syndrome (Crs).
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!